KPV (10 mg Vial) Dosage Protocol
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone). It retains the anti-inflammatory properties of the full alpha-MSH molecule and is studied primarily for gut inflammation, inflammatory bowel conditions, and wound healing models.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Routes: Subcutaneous, oral (stable to GI), or topical | Frequency: Once or twice daily
| Protocol | Daily Dose | Route | U-100 Units | Notes |
|---|---|---|---|---|
| Conservative | 500 mcg (0.5 mg) | Sub-Q | 10 units (0.10 mL) | Starting dose |
| Standard | 1.0 mg | Sub-Q or oral | 20 units (0.20 mL) | Gut inflammation focus |
| Advanced | 2.0 mg | Sub-Q | 40 units (0.40 mL) | Split twice daily |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water.
- Inject slowly down the vial wall.
- Gently swirl until dissolved.
- Refrigerate at 2–8°C; use within 28 days.
Supplies Planning
| Item | 8 Weeks (1 mg/day) | 12 Weeks |
|---|---|---|
| KPV vials (10 mg each) | 6 vials | 9 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3 × 10 mL |
| Alcohol swabs | 2 × 100-pack | 2 × 100-pack |
Mechanism of Action
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH, 13 amino acids). Studies have shown that the tripeptide C-terminal fragment retains the full anti-inflammatory activity of the parent molecule despite its minimal size.
Its primary proposed mechanism is through melanocortin receptors (particularly MC1R) and direct inhibition of NF-κB pathway activation — a master regulator of inflammation. In gut epithelial research models, KPV has been shown to reduce TNF-α, IL-6, and other pro-inflammatory cytokines, and to promote mucosal healing. Its oral stability is attributed to resistance of the Pro-Val amide bond to most peptidase enzymes.
Research Findings & Safety Profile
- Retains full anti-inflammatory activity of alpha-MSH despite being only 3 amino acids.
- Gut mucosal research: reduces colonic inflammation markers in IBD animal models.
- Oral bioavailability demonstrated in animal models — unusual for peptides of even this size.
- Inhibits NF-κB signaling pathway — direct anti-inflammatory mechanism.
- Well-tolerated in preclinical studies; mild side-effect profile.
- Often researched alongside BPC-157 for gut healing protocols with complementary mechanisms.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months | Dry, dark, minimize moisture |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days | Avoid freeze-thaw |